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Abstract 
In vitro maturation (IVM) is a promising assisted reproductive technology (ART) for 
human infertility treatment. However, when cumulus oocyte complexes (COCs) are 
removed from their follicular environment when manipulated in vitro, it can lead to a 
decrease of intra-oocyte cyclic adenosine 3’, 5’-monophosphare (cAMP) causing 
spontaneous nuclear maturation and an asynchrony with the oocytes’ cytoplasmic 
maturation, resulting in poor embryo developmental outcomes. Nuclear and 
cytoplasmic synchrony is important during oocyte maturation within antral follicles.  
It is maintained partially by the actions of c-type natriuretic peptide (CNP) binding 
with natriuretic peptide receptor 2 (NPR2), supporting high cAMP levels thus holding 
the oocyte in meiotic arrest. Addition of CNP to pre-IVM media has the capacity of 
maintaining cAMP levels and thus improve synchrony. Moreover, in women with 
advanced maternal age, successful IVM of aging oocytes faces significant challenges 
due to the morphological and cellular changes.  Inhibiting initiation of nuclear 
maturation by cAMP modulator, CNP during pre-IVM period and thus improve oocyte 
developmental competence regardless of oocyte age. 
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INTRODUCTION 
 Modern approaches to ART and the increasing 
demand from patients for a safe, less invasive and 
cheaper treatment, that also induce less side effects have 
created an important need to improve In vitro maturation 
(IVM). However, there are many debates on the efficacy 
of published IVM protocols.1-3 In vitro maturation 
(IVM) is a fertility treatment in which immature 
cumulus-oocytes complex (COCs) are extracted from 
antral follicles and matured in vitro before being 
fertilized.4  IVM of human oocytes is an attractive 
fertility treatment for women who otherwise have a 
contraindication to stimulated in vitro fertilization (IVF).  
Accordingly, IVM has been proposed as an alternative 
assisted reproductive technology (ART) to significantly 
eliminate or reduce the risk of ovarian hyperstimulation 






 Moreover, IVM treatments have a reduced drug cost 
burden and more patient-friendly with less number of 
injections the patient need to have in the process 
compared with routine IVF.5 
 Another application of IVM is for fertility 
preservation in cancer patients who require potential 
oocyte-toxic cancer treatment.6  Conventional hormonal 
stimulation is not appropriate for many of these patients 
due to the tumor estrogen sensitivity in which the tumor 
will be exacerbated by exogenous stimulation.5  
Additionally, there is an urgency associated with onco-
fertility preservation and patient can face a very 
challenging decision regarding delaying cancer treatment 
in order to receive stimulation to preserve their fertility.7  
IVM eliminates both the waiting time and hormonal 
stimulation risks for cancer patients making it an ideal 
treatment option for these patients who are already going 
through a difficult time. 
 Despite its proven need in the ART industry, 
widespread uptake of IVM by the ART industry has not 
occurred. This is due to the relatively limited success of 
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stimulation and the lack of knowledge surrounding 
maturation mechanisms. IVM derived oocytes have 
shown poorer developmental outcomes when compared 
to in vivo matured oocytes, particularly with PCOS 
patients.8 Its use and further development as a fertility 
treatment have been relatively limited compared with 
that of classical IVF following hormonal stimulation of 
ovaries.8  The biggest challenge of inhibiting IVM 
success is the spontaneous nuclear maturation that 
occurs when immature germinal vesicle (GV) oocytes 
are removed from their follicular environment, despite 
no hormonal exposure. 9-11 This spontaneous nuclear 
maturation is asynchronous with the oocyte’s 
cytoplasmic maturation, which lags and negatively 
impacts further embryo development.  
 Aging oocytes are also associated with 
morphological and cellular changes that significantly 
lower the fertilization rates. Age causes a loss of 
mitochondrial membrane integrity in mouse oocytes as a 
result of increasing oxidative stress.11, 12 Similarly, 
during IVM culture of bovine oocytes, aging oocytes 
increase the concentration of reactive oxygen species 
(ROS), changing mitochondrial activity and ATP 
content.13 It is very important to find technologies to 
regulate oocyte aging and improve fertilization 
efficiency to further benefit ART which further studies 
are required.  
 
CLINICAL APPLICATION OF IVM 
 IVM has been proposed as a viable treatment option 
for certain patient groups who are seeking ART 
treatment, such as women with POCS8 , normal 
ovulatory with PCO14, fertility preservation15, poor 
ovarian responders16, patients with an unexplained 
condition such as poor embryo development17 and rare 
situations such as nil mature oocytes in a stimulated 
cycle.18  The IVM process involves aspiration of 
immature oocytes from antral follicles and in vitro 
culture to promote maturation.18   Young women with 
PCOS still have a larger number of small follicles within 
the ovaries, which indicates the potential of pregnancy.  
 Polycystic ovary syndrome is the most common 
endocrine disorder causing ovarian dysfunction and 
anovulatory infertility.19,20 Some PCOS patients respond 
well to the drugs that control ovarian hyperstimulation 
and IVF.21 However, those drugs need to be injected 
daily and are related to a high cost burden. In addition, 
stimulation of ovulation in PCOS women may cause 
multiple pregnancies due to the development of 
numerous follicles as well as increasing the risk of 
OHSS.21 Immature oocytes are aspirated without 
hormonal stimulation to avoid the related side effects in 
IVM treatment. Therefore, in the context of PCOS, IVM 
has been suggested to overcome these problems and 
achieved a successful pregnancy.21,22  
 Although patients with advanced maternal age 
(AMA) are believed to be more prone to chromosomal 
aneuploidies23,24 and the associated higher abortion rates 
and reduced implantation rates25-27, a few studies have 
shown that a higher risk of aneuploidy has been found in 
early stage IVF embryos25,28,29 suggesting that stimulated 
IVF may not be considered the best ART treatment for 
advanced maternal age women. These risks have been 
estimated to rise from 1.9% aneuploidy embryos from 
25-29 years old women to 19.1% in women aged 40 years 
or older.30 These aneuploidies are believed to be the result 
of non-disjunction during the first meiotic division.30,31 
 IVM has been successfully applied to an extensive 
variety of infertile women. Positive ART outcomes have 
been reported in onco-fertility preservation patients, 
AMA patients and PCOS patients, demonstrating the 
high potential of this technology, such as women who 
want to avoid the hormone stimulation because of 
repeated cycles without success, or may undergo 
radiation or chemotherapy treatment and don’t have 
enough time to undergo hormone stimulation. Overall, 
advanced maternal age women are also a good target 
group to consider the possible benefit of IVM.  
 
CURRENT CHALLENGES IN IVM  
 Pincus and Enzmann have first described the concept 
of IVM on rabbit oocytes.9   Edwards then performed 
IVM of human oocytes and found that the immature 
oocytes reached metaphase II (MII) in vitro.10  In 1970, 
Cross and Brinster applied IVM by administering 
gonadotropin priming of mice and successfully produced 
healthy offspring32.  Later on, Cha et al.  conducted a 
study of IVM on human oocytes and reported a 
successful pregnancy and live birth with immature 
oocytes collected from the unstimulated ovaries.18  Since 
then, IVM has been widely accepted as a successful 
treatment for groups of infertile patients.  
 Although IVM has been considered a new ART 
technology since the first healthy baby was delivered 
from a PCOS patient22, clinical pregnancy rates of IVM 
treatment correlated with the number of oocytes retrieved 
have not been efficient: 38.5%5, 21.5% 8, and 22.5%.33  
Sanchez et al. revealed that retrieval of a large number of 
oocytes at once might not allow normal homogeneous 
development over the full cohort due to the variations of 
oocyte size, chromatin formation and mitochondrial 
formation.34  Age-related reduction in oocyte quality is 
also a factor that leads to lower the maturation and 
implantation potential for aging women.35,36  The studies 
showed that women with advance maternal age often 
have poorer oocyte developmental competence, resulting 
in a significant decrease in embryonic development 
following IVF.37-39  The reduced developmental 
competences are also likely to contribute to poor 
implantation and pregnancy rates in human IVM.   
 Another major hurdle is the synchronization of 
nuclear and cytoplasmic maturation, what is required to 
achieve full oocyte competency. The reason behind this 
problem is due to the physical removal of immature 
mammalian oocytes from antral follicle that results in 
spontaneous meiotic resumption9-11 This spontaneous 
nuclear maturation is without hormone stimulation and is 
thought to be triggered by low levels of cAMP in vitro 
40,41, thereby significantly decrease the oocyte 
developmental competency.  
 A large number of studies have confirmed that 
physically aspirating COCs from their antral follicles 
may cause spontaneous meiotic resumption in mouse 42-
44, bovine 45, goat 46 and pig 47,48 oocytes. This 
accumulating evidence suggests that cAMP 
concentration may be a factor in controlling the 
spontaneous nuclear maturation, the regulation of cAMP 
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meiotic arrest in order to synchronize cytoplasmic and 
nuclear maturation in vitro, thereby improving IVM 
oocyte developmental competency1,42,43 
 The strategies used in attempt to improve IVM, such 
as combining hormonal priming, while also adjusting the 
IVM culture media may have themselves resulted in low 
efficacy of true IVM. Some studies have focused on 
improving IVM culture media, such as a two-step culture 
protocol 1,3,42, and other studies have focused on 
optimizing the quality of the oocytes by giving human 
chorionic gonadotrophin (hCG) or follicle-stimulating 
hormone (FSH) priming 49,50 which has been named 
pseudo-IVM. In vitro maturation (IVM) treatment for 
women with PCOS has involved the use of hormonal 
priming, thus could be classed as pseudo IVM. 
According to Walls et al14, IVM patients were first 
administered 100 to 150 IU of recombinant follicle-
stimulating hormone (rFSH) for 3 to 6 days in order to 
stimulate antral follicles growth. In patients with PCOS, 
the administration of hCG has continued to be used and 
has also been adopted by other groups in the setting of 
fertility preservation for cancer patients.51 The study 
showed that pregnancy rates obtained from unstimulated 
ovaries were similar to those of patients who had 
stimulated treatment (40%),52 thus showing that hCG 
given in vivo is not necessary. Likewise, hCG in the in 
vitro system has been used for the culture of immature 
oocytes of women with PCOS. Ge et al. reported that the 
addition of hCG to culture medium did not improve 
oocyte maturation.53  
 Despite some improvement in oocyte maturation 
rates and pregnancy rates, immature oocytes may be at 
different stages of development and thus a standardized 
IVM protocol could not be established. There are still 
many controversial areas of debate regarding hormone 
stimulation and the optimal IVM protocol. Data from 
previous studies can assist in tailoring an IVM system 
that promotes synchronization of nuclear and 
cytoplasmic maturation of oocytes. Further research 
would focus on improving the two-step IVM protocol in 
order to control resumption of mammalian oocyte 
meiosis. The aim of future research is to establish an 
IVM culture system using unprimed young mice oocytes 
and determine if the same system can be applied to both 
young and aged oocytes.   
 
OOCYTE DURING FOLLICULAR 
DEVELOPMENT 
 Folliculogenesis is the complex progression of the 
resting primordial follicles through primary, preantral 
and finally to the antral follicle whereby the oocyte 
within gains the ability to mature, fertilize and achieve 
competency.  Developing follicles regularly leave the 
non-growing primordial follicle pool to join the growing 
pool, and the undergo atresia before puberty. After 
puberty, there is a continuous recruitment of follicles 
from the primordial follicle pool to form primary 
follicles. The oocyte contained within a primary follicle 
has a single layer of granulosa cells, which become 
cuboidal and proliferative.54  
The secondary follicles are now responsive to the 
gonadotrophins FSH and LH, and the growing oocytes 
are surrounded by several layers of cuboidal granulosa 
cells. 55,56  Oocytes are meiotically incompetent at this 
stage.  During the early antral follicle stage, granulosa 
cell secretions result in the development of an antrum 
with follicular fluid. The transition from a preantral to an 
antral follicle is dependent upon the synthesis of steroid 
hormone gonadotrophins. Antral follicles are also known 
as tertiary follicles. The majority of these oocytes are 
meiotically competent. At this stage, appropriate 
gonadotrophins may sustain optimal follicular 
development. In addition, during this stage and with the 
influence of FSH, granulosa cells start differentiating and 
producing estrogen.55,56 
 During the pre-ovulatory stage, further proliferation 
of granulosa cells occurs and is comprised of cumulus 
cells and mural granulosa cells. Under the influence of 
the preovulatory gonadotrophins surge, oocytes continue 
to develop until they obtain competence to resume 
meiosis and progress to metaphase II before ovulation. 
During the follicular growth, granulosa cells play a 
crucial role in supporting oocytes to obtain 
developmental competence.57,58  Cumulus cells also start 
producing hyaluronic acid, which is deposited into the 
intercellular space causing the space between the 
cumulus cells to expand.59 In conjunction with the 
supporting cells, the growing oocyte also regulates the 
proliferation, differentiation, extracellular matrix and 
hormone activation of granulosa cells via gap junctions.60 
 
OOCYTE MATURATION   
 In most mammals, intact immature cumulus-oocyte 
complexes (COCs) are arrested at the prophase I stage.61  
These immature eggs undergo many dynamic events to 
ensure the maturation of oocytes, including the 
resumption of meiosis, germinal vesicle breakdown 
(GVBD) which results in chromosome condensation and 
polar body extrusion.61  Oocyte maturation is comprised 
of nuclear maturation and cytoplasmic maturation. The 
nuclear maturation is the resumption of the first meiotic 
division, from prophase I to metaphase II of meiosis.62  
The nuclear maturation process is defined by 
morphological changes within the oocyte.  Ovulated 
oocytes are halted in metaphase II until fertilization.63  
 
NUCLEAR MATURATION  
 The nuclear maturation process is mainly 
characterized by morphological chromosomal changes 
during meiosis, such as chromosomal segregation and 
alignment. Before meiotic resumption, the intact nuclear 
structure of the oocyte contains diffuse chromosomes 
known as a germinal vesicle (GV).64 During meiotic 
resumption, GVBD occurs, chromosomes start migrating 
to the pole and beginning division. The nuclear 
membrane vanishes. GVBD leads to chromosomes 
condensing and RNA synthesis ceasing.65,66  
 The majority of mammalian oocytes are arrested in 
meiosis I in the antral follicles; the occurrence of nuclear 
maturation (also known as meiotic resumption) is 
associated with the presence of luteinizing hormone 
(LH). 67-69   GVBD is the only morphological change that 
can be easily observed during oocyte meiotic 
resumption.70  However, physically removing the oocytes 
from the antral follicles can cause spontaneous meiotic 
resumption in the in vitro environment.9-11  The 
completion of the nuclear maturation process during IVM 
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oocyte is completed.71,72   Vivarelli et al.   discovered 
that the maintenance of high levels of cAMP could be an 
effective means to inhibit GVBD.40   In addition, this 
nuclear maturation process is regulated by the oscillating 
activation of a cytoplasmic maturation-promoting factor 
(MPF).64  High levels of MPF initially induce not only 
GVBD, but also sustain chromosome condensation. The 




 Oocyte cytoplasmic maturation refers to a series of 
complicated molecular changes, including the 
accumulation of mRNA, proteins, nutrients and other 
substrates, which are required for the activation of the 
oocyte and formation of pronuclei.73,74  These molecular 
changes enable oocytes to acquire developmental 
competence in order to support fertilization and 
preimplantation development.64  
 Some aspects of cytoplasmic maturation are 
associated with nuclear maturation. For example, 
oocytes undergo early stage of cytoplasmic activation by 
releasing low levels of intracellular calcium iron (Ca2+) 
in response to microinjection of inositol triphosphate 
(IP3), and when the intracellular Ca
2+ levels reach a 
threshold, nuclear maturation will occur.75   Wang et al. 
found that heat stress had a detrimental effect on the 
cytoplasmic competency rather than the nuclear 
competency of mouse oocytes, thereby decreasing 
blastocyst rates.72 The experiment of exchanged 
chromosomal spindles between metaphase II oocytes 76 
and between aged and fresh oocytes 77 showed that the 
poor oocyte developmental competence was 
predominantly affected by cytoplasmic components. 
These findings indicate that activation of cytoplasmic 
maturation is more susceptible to environmental changes 
compare to nuclear maturation during oocyte 
development such as heat stress.  
 
RESUMPTION AND ARREST OF MEIOSIS  
 Meiotic resumption and arrest is greatly dependent 
on a delicate balance between the levels of factors 
maintaining the oocyte in arrest and the levels of factors 
stimulating oocyte maturation. The total number of 
oocytes is to be produced in a lifetime which are arrested 
at an early stage of the first meiotic division are present 
prior to birth in most newborn mammalian species.78,79  
 Before the LH surge, these immature oocytes obtain 
meiotic capability at the time of antrum construction 
completion (Erickson & Sorensen 1974), and this time is 
synchronized when the oocyte reaches a maximum level 
of cyclin-dependent kinase (CDK1) and cyclin protein.79  
These competent oocytes are then arrested at prophase I 
until the preovulatory surge of LH. A large number of 
studies have confirmed that cAMP can be produced by 
the oocyte or by the granulosa cells, and is transported 
via gap junctions to inhibit meiotic resumption.80  
Spontaneous nuclear maturation is due to oocytes being 
removed from their follicular environment can be 
prevented by a cAMP modulator, such as CNP1,11 or 3-
isobutyl-1-methylxanthine (IBMX) 47 in the pre-IVM 
culture medium. The surge of LH binds with its receptor, 
which is primarily expressed by granulosa cells that 
enable oocytes to undergo meiotic resumption. As 
cumulus cells and oocytes lack LH receptors, the LH 
signal indirectly triggers resumption of meiosis.82,83   
 Oocyte meiotic competence is also related to other 
factors. Oocytes retrieved from larger follicles had better 
development compared to smaller follicles.84,85  In 
addition, the size of mammalian follicles can be used as 
a non-invasive marker to determine the developmental 
ability of oocytes and improve reproductive outcomes. 
Specific follicle with diameter of 300-350μm had 
significantly higher percentage of MII and the best 
oocyte development to blastocysts in mice85   Other than 
that, maturation-promoting factor (MPF) normal activity 
depends on the same amount of kinase catalytic p34cdc2 
subunit protein86   and B-type cyclin protein present86,87   
Pig oocytes isolated from preantral follicles less than 
80μm indicated that the p34cdc2 subunit of MPF levels is 
limited during the early stage of follicular growth.88  A 
diameter of 90μm in pig oocytes indicated that p34cdc2 
catalytic subunit and B-type cyclin levels are relatively 
higher compared with those of fully-grown oocytes.89  
Furthermore, activation of MPF can also trigger meiotic 
resumption. The components of MPF, p34cdc2 catalytic 
subunit and B-type cyclin are also present in meiotically 
dividing oocytes89 MPF increases in the growing oocytes, 
and oocytes acquire meiotic competency when MPF 
reaches its threshold levels.90  
 The increasing estrogen levels trigger a significant 
spike in LH, causing release of the oocyte from the 
mature follicle and activation of oocyte maturation. The 
corpus luteum (ruptured follicle) starts secreting 
progesterone and estrogen in order to prepare the uterus 
for pregnancy.91  The levels of cAMP in the oocyte and 
granulosa cells are reduced just before ovulation and 
thereby decreasing its inhibitory impact on meiosis. 
Following MPF activation, the breakdown of the 
germinal vesicle drives the oocyte towards meiosis.92  
After GVBD, the ovulated oocyte is halted at the 
metaphase II until fertilization. Sperm fusion with the 
oocyte causes an increase in intracellular Ca2+ and 
initiates the breakdown damage of endogenous cyclin. 
The onset of the chromosome segregation during the 
transition from metaphase to anaphase enables the oocyte 
to complete meiosis. At this stage, chromosome 
segregation errors can lead to aneuploidy, and women 
with advanced maternal age have increased risk of 
aneuploidy that can result in miscarriage later in the 
pregnancy.93   
 
CYCLIC NUCLEOTIDE AND CONTROL OF 
OOCYTE MATURATION  
 The cyclic nucleotides, including cAMP and cyclic 
guanosine monophosphate (cGMP), play a critical role in 
regulation of mammalian oocyte meiotic arrest and 
resumption in vitro42 (Li et al. 2016). The cAMP is an 
essential signaling molecule, which is synthesized from 
adenosine triphosphate (ATP) by active G-protein 
coupled receptors and membrane-bound adenylate 
cyclase within the cell.94,95  It can also be produced from 
cumulus cells as the result of LH or FSH stimulation, and 
is continuously supplied to the oocyte through gap 
junctions.58,96   Phosphodiesterases (PDE3A) is a second 
regulator for cAMP levels in oocytes and it is involved in 
the hydrolysis of the cyclic phosphate bond in cGMP and 
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is synthesized from the natriuretic peptides pathway. 
Those guanylin peptides bind transmembrane guanyl 
cyclase, which catalyses the conversion of guanosine 
triphosphate (GTP) into cGMP. Much like cAMP, the 
cGMP acts as a second messenger to active intracellular 
protein kinase phosphorylation and impacts the effect of 
different PDE3A. 41 
 Before the LH surge, high levels of oocyte cAMP 
keep the oocyte meiotically arrested. The granulosa cells 
also supply cGMP to the oocyte which inhibits PDE3A 
activity. After the LH surge, cGMP levels decrease and 
induce a secondary cascade of epidermal growth factor 
(EGF-like protein) in the granulosa cells of the follicle, 
showing this cascade is required for oocyte maturation.81   
In response to LH, cAMP levels increases, and the high 
levels of cAMP affect the cumulus cells and interrupt 
communication in the COCs.58   Under these conditions, 
the flow of cAMP to the oocyte decreases, PDE3A 
inhibition is relieved and meiosis is resumed.81  (Figure 
1). 
 It has been identified that meiotic arrest of oocytes in 
vitro is dependent on the preservation of high levels of 
cAMP within oocytes.100 The cAMP is maintained 
within oocyte through two mechanisms. Firstly, oocytes 
can autonomously produce cAMP, the expression of G-
protein coupled receptor 3 and 12 (GPR3 and GPR12) is 
responsible for the regulation of cAMP levels in the 
oocyte.95   Secondly, FSH or LH triggers the production 
of cAMP in the cumulus cells and flows to the oocyte 
through gap junction.58,96 This is the main source of 
cAMP supply to the oocyte to maintain meiotic arrest 

















Figure 1. Proposed model depicting the role of CNP, cAMP 
and cGMP in maintenance of mammalian oocyte meiotic arrest 
before LH surge and the LH signaling pathway of mammalian 
oocyte resumption. First pathway of cAMP is synthesized from 
ATP by activation of G-protein coupled receptor (GPR) with 
adenylate cyclase (ADCY). It is the mainly source of cAMP 
supplies to the oocyte by cumulus cells via gap junction to 
maintain meiotic arrest. Secondary pathway of intra-oocyte 
cAMP is produced by the expression of G-protein coupled 
receptor 3 and 12 (GPR3 and GPR12) with ADCY. Before LH 
surge, binding of CNP with NPR2 increase the levels of cGMP, 
which inhibits PDE3A activity, thus maintain cAMP levels 
within oocyte. High levels of cAMP sustain meiotic arrest. 
After LH surge, the activation of EGF-like protein pathway 
interrupts the expression of CNP with NPR2, the levels of 
cAMP decrease enabling oocyte resumed81.  
 
 The cAMP and cGMP production are self-regulated. 
Törnell et al. investigated the function of cGMP during 
rat oocyte maturation, and they reported that cyclic GMP 
is an effective inhibitor of cAMP degradation; thereby 
regulation of PDE3A and low levels of cGMP would 
contribute to spontaneous meiotic resumption in vitro.41 
In addition, Norris et al.  showed that cGMP enzyme is 
generated in cumulus cells, and it permeates from the 
cumulus cells into the oocyte to inhibit cAMP hydrolysis 
by PDE3A through gap junctions.81  Taken together, these 
promising results provide confirmation that the 
concentration of cAMP must be maintained at optimum 
levels to assure oocyte meiotic arrest.  
 
PROBLEM RELATED TO OCYTES FROM AGED 
MOTHERS 
 Women’s fertility declines with advancing age from 
the mean age of 30 years-old and declines more 
significantly when ≥ 35 years-old which results in the 
progressive decreased oocyte number and poor oocyte 
quality.16   Lower pregnancy rate was found in women 
with advanced maternal age largely as a result of the 
higher aneuploidy rate compared to younger women.  
The effect of aging also causes complex cellular and 
molecular changes in oocytes.101 and the changes of 
which may affect normal embryo development and result 
in early pregnancy loss in humans.  Recent studies on 
murine oocytes have shown that the aging of oocytes can 
cause a loss of mitochondrial membrane integrity as a 
result of increasing oxidative stress.10,46   The study has 
identified that oxidative stress acts as a key mediator, 
which regulates the intrinsic apoptotic pathway in the 
aged oocytes, thus, the oxidative stress raised as oocyte 
age increased result in negative effect on oocyte 
development.10  
 Chromosomal segregation errors can occur during 
both mitotic and meiotic divisions. During the second 
meiotic cell division, chromosomal segregation errors 
can cause DNA damage and incorrect chromosome 
number. Aneuploidy is a direct consequence of 
chromosome segregation error in meiosis. As a result, 
aneuploidy of fertilized eggs and embryos can cause 
miscarriage or with trisomy such as Down syndrome.93  
This result was consistent with the study by Loane’s team 
that the risk of children born with Down syndrome 
increased in women at advanced maternal age.102   The 
risk of women conceiving a child with DS is 1 in 1400 
births at age 24, 1 in 350 at age 35 and increases to 1 in 
25 by age 45.  Moreover, the two core subunits of meiotic 
cohesion complex SMC1B and REC8 have a critical role 
to ensure precise distribution of chromosomes during 
meiosis. In Yoon et al.’s study showed that the decrease 
in cohesion concentration is associated with age-related 
meiotic segregation errors in mammalian oocytes.103 
Compared with a 20-year-old, the levels of SMC1B and 
REC8 are significantly decreased in women who are 40 
years old.93 
 
DETRIMENTAL EFFECTS OF OOCYTES FROM 
WOMEN WITH ADVANCED MATERNAL AGE 
IN AN IVM SYSTEM 
 The aging of oocytes is a key factor that compromises 
the overall quality of oocytes during IVM culture, which 
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development. Increased ROS production in aging 
oocytes subsequently causes the release of cytochrome 
c, which is involved in a key apoptotic pathway.104  
 The reactive oxygen species (ROS) can diffuse 
through cell membranes and significantly damage 
biological molecular structures, including nucleic acids, 
lipids and protein, resulting in dysfunctional 
mitochondria and apoptosis.61  Excessive levels of ROS 
are associated with meiotic arrest in human oocytes and 
cell death in mouse embryos.105   In addition, an 
increased concentration of glucose increases the 
generation of ROS during oocyte maturation. When the 
levels of ROS exceed normal physiological conditions, 
the resultant oxidative stress can reduce oocyte quality 
in the mouse.61  
Prolonged maturation culture could reduce the quality of 
mammalian oocytes and induce ageing of the oocytes 
during the MII arrest period.106  The study has found that 
the percentage of mature bovine oocytes reached the 
highest level after being cultured for 22 hours, compared 
with oocytes cultured for 28 or 34 hours. The aged 
oocytes were more likely to undergo germinal vesicle 
breakdown (GVBD) from germinal vesicle (GV) stage 
during the maturation culture period.106   Faster 
developing immature oocytes showed an increased 
activation, a higher spontaneous fragmentation rate and 
a decrease in maturation promoting factor (histone H1 
kinase) activity.107   Moreover, the activity of histoneH1 
kinase is related to the competency of the cytoplasm of 
the oocyte.107   It can be seen that cytoplasmic changes 
affect oocyte quality when the meiotic arrest period is 
prolonged. Additionally, one study has shown that in 
vitro aged oocytes lost the microfilament-rich area over 
the meiotic spindle first, then disrupted spindle location 
and subsequently misplaced chromatin organization. 
These abnormal morphological changes of in vitro aged 
oocytes are similar with that occurring with in vivo 
ageing.108  
 The development of a three-dimensional (3D) matrix 
has provided a valuable in vitro model to investigate the 
regulation of folliculogenesis in prepubertal, young and 
older adult monkey.7   In this study, compared with 
follicles from older adult monkeys, there was a larger 
percentage of secondary follicle survival from 
prepubertal and young monkey during the culture period. 
The lower surviving follicle rate obtained from older 
monkeys might be due to the preantral follicles dying as 
a result of lack of apoptosis inhibiting factor.109   
Alternatively, the activation of other factors responsible 
for follicle atresia during early follicular development 
increased as a result of the aging process.110  
 Taken together, the maturation culture period is 
important for oocyte maturation and subsequent 
successful fertilization. The mechanisms of prolonged 
meiotic arrest resulting in poor survival rate of follicles 
may be relevant to the declining reproductive ability of 
older women. These features of ovarian aging, including 
poor oocyte quality or decreased survival rate are 
frequently observed clinically in patients with advanced 
maternal age7  
 
CONCLUSIONS AND NEW PERSPECTIVES 
 It is widely accepted that high levels of cAMP within 
mammalian oocytes during IVM could sustain oocyte 
meiotic arrest and substantially synchronize nuclear and 
cytoplasmic maturation, thus improve oocyte 
developmental competence. The communication 
between oocyte and the surrounding cumulus cells via 
gap junctions diffuses the levels of cAMP and cGMP in 
supporting oocyte meiotic arrest and resumption. The 
cAMP levels are produced from the ATP by the 
activation of GPR with ADCY, which is continually 
supplied to the oocyte by cumulus cells via gap junctions. 
A large number of studies have suggested that pre-IVM 
step medium supplemented with cAMP modulator, such 
as CNP, acts as the main defense factor against 
‘spontaneous’ maturation, which can regulate the period 
of nuclear maturation. One of the cAMP modulators, 
CNP, binding with its cumulus cell receptor NPR2, 
effectively regulates the levels of cGMP in order to 
maintain ideal concentrations of cAMP within oocytes. A 
relative high level of cAMP extends the duration of 
nuclear maturation, which improves the synchronization 
of cytoplasmic and nuclear maturation and contributes to 
further sustained acquisition of developmental 
competence of oocytes. The duration of nuclear 
maturation plays a critical role in supporting oocyte 
maturation and is a crucial factor that can enhance IVM 
efficiency.  
 A two-step IVM system with different cAMP 
modulators to regulate levels of cAMP during pre-IVM 
phase is needed. However, enhancement of IVM culture 
conditions is complicated as it depends not only on the 
use of different cAMP modulators, but also many other 
factors. Firstly, cAMP modulators can differently 
influence the oocytes according to developmental stage 
in different mammalian species. For instance, IBMX may 
effectively inhibit some mammalian oocytes resumption, 
however, it is not able to maintain pig oocyte meiotic 
arrest during the pre-IVM phase. The duration of the pre-
IVM phase and the concentrations of cAMP modulator 
also need to be considered. Secondly, even though a large 
number of studies have concluded that two-step IVM 
system improve oocyte developmental competency, 
these COCs were retrieved from hormone-stimulated 
ovaries.  
 In current IVM protocols, serum, hormone and 
growth factors have been identified as the key factors, 
however, synchronization of nuclear and cytoplasmic 
maturation during IVM is also important for the 
proportion of oocytes matured to MII and further oocyte 
developmental competence. Regulation of cAMP during 
the pre-IVM phase may be a solution to the current 
discrepancies in the literature and may promote oocytes 
to acquire developmental competency, with particular 
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